Published in Lancet on November 08, 2011
Limus Eluted From A Durable Versus ERodable Stent Coating (LEADERS) | NCT00389220
BES, EES, and ZES-R in Real World Practice (CHOICE) | NCT01397175
The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol (2012) 1.35
Macroscale delivery systems for molecular and cellular payloads. Nat Mater (2013) 1.25
Stent evaluation with optical coherence tomography. Yonsei Med J (2013) 0.92
Bioresorbable scaffolds in the treatment of coronary artery disease. Med Devices (Auckl) (2013) 0.90
Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn-Alloys. Adv Healthc Mater (2016) 0.85
Vascular restoration therapy and bioresorbable vascular scaffold. Regen Biomater (2014) 0.84
Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. Int J Cardiovasc Imaging (2014) 0.84
No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. Expert Rev Cardiovasc Ther (2012) 0.81
Percutaneous coronary intervention in patients with diabetes: current concepts and future directions. J Diabetes Sci Technol (2014) 0.81
Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. PLoS One (2013) 0.80
Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STEnt IN patients with coronary artery disease) Registry. Einstein (Sao Paulo) (2013) 0.80
One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India. Indian Heart J (2013) 0.78
A bumpy and winding but right path to domestic drug-eluting coronary stents. Korean Circ J (2013) 0.77
Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents. PLoS One (2013) 0.77
Advances in stent technologies and their effect on clinical efficacy and safety. Med Devices (Auckl) (2014) 0.77
Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. Eur J Med Res (2015) 0.77
Efficacy and safety of a biodegradable polymer sirolimus-eluting stent in primary percutaneous coronary intervention: a randomized controlled trial. Arch Med Sci (2013) 0.77
Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography. Int J Cardiovasc Imaging (2013) 0.76
Optimal choice of coronary revascularization and stent type in diabetic patients with coronary artery disease. Cardiol Ther (2013) 0.75
Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview. Indian Heart J (2013) 0.75
Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. Indian Heart J (2014) 0.75
Can long-term results following balloon angioplasty be the "crystal ball" to predict outcome following bioresorbable vascular scaffolds? J Am Heart Assoc (2012) 0.75
Clinical impact of routine follow-up coronary angiography after second- or third-generation drug-eluting stent insertion in clinically stable patients. Korean J Intern Med (2014) 0.75
Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes. Medicine (Baltimore) (2016) 0.75
Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis. Thromb J (2012) 0.75
Controversies in the use & implementation of drug-eluting stent technology. Indian J Med Res (2012) 0.75
Coronary stent thrombosis: current insights into new drug-eluting stent designs. Chonnam Med J (2012) 0.75
Polymer drug-eluting stents: is the future biodegradable? Lancet (2011) 0.75
Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study. Scientifica (Cairo) (2016) 0.75
Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. Med Devices (Auckl) (2015) 0.75
Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India. Indian Heart J (2013) 0.75
Extracting information from free-text electronic patient records to identify practice-based evidence of the performance of coronary stents. PLoS One (2017) 0.75
Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent. J Mater Sci Mater Med (2017) 0.75
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med (2009) 13.42
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Universal definition of myocardial infarction. Circulation (2007) 11.69
Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med (2006) 11.66
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ (2002) 7.26
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med (2007) 6.17
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ (2010) 5.68
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med (2010) 5.43
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol (2013) 5.11
Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02
Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol (2011) 4.99
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94
Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med (2012) 4.87
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J (2006) 4.69
High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med (2015) 4.68
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imaging. J Am Coll Cardiol (2006) 4.37
Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med (2014) 4.37
Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. EuroIntervention (2013) 4.30
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Sleep duration and mortality: a systematic review and meta-analysis. J Sleep Res (2009) 4.09
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol (2005) 4.05
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention (2015) 4.00
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol (2007) 3.82
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med (2015) 3.81
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60
All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ (2011) 3.51
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47